Acapatamab

DB18838InvestigationalProtein Based Therapies

Acapatamab is under investigation in clinical trial NCT04631601 (Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (Mcrpc)).

Mechanism: Pharmacologically active on T-cell surface glycoprotein CD3 epsilon chain, Glutamate carboxypeptidase 2, and T-cell surface glycoprotein CD3
Curator reviewed
Also known as: Mmunoglobulin scfv-scfv-scfc, anti-(homo sapiens folh1 (folate hydrolase, prostate specific membrane antigen, psma)) and anti-(homo sapiens cd3e (cd3 epsilon, leu-4)), monoclonal antibody single chain (scfv)2-scfc, bispecific
Code names: AMG-160

Resolves to

Compound

UNIIGW5EID3IDOCAS2314491-93-3

Targets

P07766CD3EQ04609FOLH1

What you can answer from here — as of July 09, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Acapatamab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account